Bearish
HSBC downgrades Pfizer to 'Hold' with $28 price target due to pipeline concerns
HSBC has downgraded Pfizer's stock rating from 'Buy' to 'Hold' and reduced its price target to $28, citing a lack of near-term catalysts and reduced confidence in the company's pipeline, particularly following a Phase 3 setback in non-small cell lung cancer. The revised price target suggests approximately 17% upside from the current stock price of $24.32.
Key points
- HSBC downgrades Pfizer's stock rating to 'Hold' and lowers price target to $28.
- Pfizer's stock is currently trading at $24.32, approximately 5% above its 52-week low of $23.11.
- The stock offers a 7.07% dividend yield, with a consensus price target of $28.82.
- Pfizer's recent quarterly earnings report showed earnings per share of $0.75 on revenue of $14.45 billion, with revenue rising 5.4% year over year.
Sources
- HSBC downgrades Pfizer stock rating on lack of near-term catalystsInvesting.com · July 6, 2026
- Pfizer Inc. $PFE Shares Sold by Hsbc Holdings PLCMarketBeat · June 20, 2026
- Pfizer Declares Second-Quarter 2026 DividendStockTitan · April 22, 2026
- Pfizer Q1 Profit Drops, Revenues Rise; Backs FY26 Outlook - UpdateRTTNews · May 5, 2026
AI-generated from public news sources. Not financial advice.
